EZH2 and follicular lymphoma: To date, multiple inhibitors targeting EZH2 have been reported, of which Tazemetostat was approved by the Food and Drug Administration (FDA) in January 2020 for the treatment of advanced epithelioid sarcoma and follicular lymphoma [276,277].